Clinical Trial Update: Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating aripiprazole for neuroleptic-induced tardive dyskinesia is being tracked, with the current trial status listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan | Conditions: Dyskinesia, Drug-Induced | Phase 4 | Status: UNKNOWN